Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vir Biotechnology Inc
(NQ:
VIR
)
9.440
-0.120 (-1.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vir Biotechnology Inc
< Previous
1
2
Next >
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
May 17, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
May 15, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
May 11, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 04, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
May 03, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
May 02, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
March 08, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
February 28, 2023
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
February 22, 2023
Final draft guidance based on cost effectiveness evaluation of sotrovimab
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 16, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
February 16, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
February 13, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
January 25, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 21, 2022
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
November 16, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
November 06, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 31, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 28, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 18, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 11, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 04, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21, 2021
From
Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.